Literature DB >> 15655606

Colorectal gastrointestinal mesenchymal tumours. Report of a stromal case of the rectum (GIST) and a leiomyosarcoma of the transverse colon.

A Michalopoulos1, V N Papadopoulos, G Basdanis, E Haralabopoulos, A Zatagias, S Netta, S Apostolidis, E Fahantidis.   

Abstract

BACKGROUND: Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours of the gastrointestinal tract. They are positive to C-kit (CD 117), more common in the older males, and mostly in the stomach, less in the colon and rectum and oesophagus. Benign tumours are more common than the malignant ones. Classification of GISTs is based on morphology and immunochemistry.
METHODS: We report two cases of colorectal gastrointestinal mesenchymal tumours, one on the transverse colon which was found to be immunohistochemically leiomyosarcoma and the other on the rectum which met the GIST criteria. The patients underwent transversectomy and abdominal perineal resection, respectively.
CONCLUSIONS: They did not receive Imanitib postoperatively and two years after there is no evidence of recurrence. Surgery is the treatment of choice for resectable GISTs, and other mesenchymal tumours benign or malignant.

Entities:  

Mesh:

Year:  2004        PMID: 15655606     DOI: 10.1007/s10151-004-0142-9

Source DB:  PubMed          Journal:  Tech Coloproctol        ISSN: 1123-6337            Impact factor:   3.781


  3 in total

Review 1.  Gastrointestinal (GI) leiomyosarcoma (LMS) case series and review on diagnosis, management, and prognosis.

Authors:  Lara Hilal; Kassem Barada; Deborah Mukherji; Sally Temraz; Ali Shamseddine
Journal:  Med Oncol       Date:  2016-01-20       Impact factor: 3.064

2.  Colorectal gastrointestinal stromal tumors: a brief review.

Authors:  Rishindra M Reddy; James W Fleshman
Journal:  Clin Colon Rectal Surg       Date:  2006-05

3.  A pooled analysis of risk factors of surgically treated leiomyosarcoma of the colon in adults.

Authors:  Yun Wang; Hao Wang; Zhi-Lu Yuan; Jing-Fei Zhao; Dian-Bo Dong; Qian Gao
Journal:  World J Surg Oncol       Date:  2020-03-28       Impact factor: 2.754

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.